Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE).

Am J Respir Crit Care Med · 2025 · PMC12180140 · PMID 40043302

Europe PMC DOI

hedged sentences

0.0976

closest p · 2.0× alpha

0.0976

boldest claim

The sentences

did not reach statistical significanceP = 0.0976so close (0.05 < p ≤ 0.1)

The placebo-adjusted difference from baseline seen in the 12.5 mg camlipixant arm did not reach statistical significance (−21.1%; 95% CI, −40.5 to 4.5; P = 0.0976).

also in 111,027 other papers

showed a trendno p-value reported

All camlipixant arms showed a trend for greater improvement in cough severity visual analog scale and Leicester Cough Questionnaire scores over placebo.

also in 53,322 other papers

nominally significantno p-value reported

Secondary Endpoints Change from baseline to Day 15 in 24-hour cough frequency Nominally significant placebo-adjusted reductions from baseline in 24-hour cough frequency were also observed at Day 15 in the 50 mg and 200 mg camlipixant arms, −32.4% (95% CI, −48.1 to −11.8; P = 0.0040) and −34.3% (95% CI, −49.9 to −14.0; P = 0.0024), respectively ( Figure 3A and Table 2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.